Patients' characteristics at enrollment (n = 92)
| Characteristic . | Value . |
|---|---|
| Median age (range), y | 64.3 (34.6-75) |
| No. (%) of patients with hepatomegaly | 10 (11) |
| No. (%) of patients with splenomegaly | 16 (17) |
| No. (%) of patients with ≥1 lymph node involved | 33 (36) |
| Mean (range) no. of mo between diagnosis and enrollment | 47 (2-224) |
| Mean (range) no. of mo between end of first-line treatment and enrollment | 3 (0-158) |
| No. of patients with first relapse | 50 |
| No. of patients with resistant disease | 42 |
| No. (%) of patients with hemoglobin level < 100 g/L | 47 (51) |
| No. (%) of patients with platelet count < 100 × 109/L | 20 (22) |
| No. (%) patients with β2 microglobulin level > 2.5 mg/L | 48 (52) |
| Median (range) IgM (g/L) | 30.5 (8.4-101) |
| No. of patients with lactate dehydrogenase level > normal | 11 |
| Characteristic . | Value . |
|---|---|
| Median age (range), y | 64.3 (34.6-75) |
| No. (%) of patients with hepatomegaly | 10 (11) |
| No. (%) of patients with splenomegaly | 16 (17) |
| No. (%) of patients with ≥1 lymph node involved | 33 (36) |
| Mean (range) no. of mo between diagnosis and enrollment | 47 (2-224) |
| Mean (range) no. of mo between end of first-line treatment and enrollment | 3 (0-158) |
| No. of patients with first relapse | 50 |
| No. of patients with resistant disease | 42 |
| No. (%) of patients with hemoglobin level < 100 g/L | 47 (51) |
| No. (%) of patients with platelet count < 100 × 109/L | 20 (22) |
| No. (%) patients with β2 microglobulin level > 2.5 mg/L | 48 (52) |
| Median (range) IgM (g/L) | 30.5 (8.4-101) |
| No. of patients with lactate dehydrogenase level > normal | 11 |